HCM HUTCHMED (China) Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1648257
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-13.0%
TTM net income YoY1,111.0%
TTM EPS YoY1,200.0%
Revenue 3-yr CAGR8.8%
Net income 3-yr CAGR—
Margins
Gross margin38.7%
Operating margin-7.1%
Net margin83.3%
FCF margin-14.4%
EBITDA margin-4.7%
Returns
ROE45.7%
ROA30.2%
ROIC (approx.)-3.5%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets28.6%
Debt / equity0.08x
Current ratio4.96x
Interest coverage-13.67x
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio34.5%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $548.51M | $630.20M | $838.00M | $426.41M | $356.13M |
| Cost of revenue | $336.35M | $348.88M | $384.45M | $311.10M | — |
| Gross profit | $212.16M | $281.32M | $453.55M | $115.31M | — |
| R&D expense | $148.29M | $212.11M | $302.00M | $386.89M | $299.09M |
| SG&A expense | $66.72M | $64.30M | $79.78M | $92.17M | $89.30M |
| Operating income | -$39.16M | -$43.70M | $18.38M | -$407.69M | -$328.32M |
| Interest expense | $2.87M | $2.87M | $759,000 | $652,000 | $592,000 |
| Pretax income | $498.69M | -$1.11M | $58.31M | -$410.42M | -$215.74M |
| Income tax | $63.61M | $7.19M | $4.51M | -$283,000 | $11.92M |
| Net income | $456.91M | $37.73M | $100.78M | -$360.83M | -$194.65M |
| EBITDA | -$25.85M | -$31.36M | $26.58M | -$399.03M | -$321.13M |
| EPS (basic) | 0.53 | 0.04 | 0.12 | -0.43 | -0.25 |
| EPS (diluted) | 0.52 | 0.04 | 0.12 | -0.43 | -0.25 |
| Weighted avg. shares (diluted) | 872.89M | 872.83M | 869.20M | 847.14M | 792.68M |
| Banking | |||||
| Deposits | $1.68M | $1.63M | $1.56M | $3.62M | $2.11M |
| Balance sheet | |||||
| Cash & equivalents | $71.33M | $153.96M | $283.59M | $313.28M | $377.54M |
| Short-term investments | $1.30B | $682.15M | $602.75M | $317.72M | $634.16M |
| Receivables | $126.75M | $155.54M | $116.89M | $97.99M | $83.58M |
| Inventory | $41.13M | $50.40M | $50.26M | $56.69M | $35.76M |
| Current assets | $1.57B | $1.07B | $1.10B | $839.89M | $1.21B |
| PP&E, net | $94.62M | $92.50M | $99.73M | $75.95M | $41.27M |
| Goodwill | $3.11M | $2.99M | $3.06M | $3.14M | $3.38M |
| Intangibles | $8.94M | — | $21,000 | $85,000 | $163,000 |
| Total assets | $1.75B | $1.27B | $1.28B | $1.03B | $1.37B |
| Current liabilities | $315.77M | $376.56M | $403.03M | $353.90M | $311.66M |
| Short-term debt | $24.97M | $23.37M | $31.16M | — | $26.91M |
| Long-term debt | $68.19M | $59.43M | $48.19M | $18.10M | $26.91M |
| Total debt | $93.16M | $82.81M | $79.34M | $18.10M | $53.81M |
| Total liabilities | $501.83M | $502.34M | $536.39M | $392.57M | $333.15M |
| Shareholders' equity | $1.24B | $759.93M | $730.54M | $610.37M | $986.89M |
| Net debt | $21.83M | -$71.15M | -$204.25M | -$295.17M | -$323.73M |
| Cash flow statement | |||||
| Operating cash flow | -$64.66M | $497,000 | $219.26M | -$268.60M | -$204.22M |
| Capital expenditure | $14.15M | $17.93M | $32.61M | $36.66M | $16.40M |
| Free cash flow | -$78.81M | -$17.44M | $186.65M | -$305.26M | -$220.62M |
| Investing cash flow | -$29.41M | -$96.06M | -$291.14M | $296.59M | -$306.32M |
| Financing cash flow | $7.84M | -$30.67M | $48.66M | -$82.76M | $650.03M |
| Depreciation & amortization | $13.31M | $12.34M | $8.21M | $8.66M | $7.19M |
| Share buybacks | — | $36.06M | $9.07M | $48.08M | $27.31M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.